RecruitingPhase 2

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

United States30 participantsStarted 2021-04-16

Plain-language summary

This is a Phase II treatment study analyzing the role of preoperative chemotherapy, preoperative laparoscopic HIPEC, and gastrectomy with CRS/HIPEC in gastric adenocarcinoma patients with cytology-positive only carcinomatosis, radiologically-occult carcinomatosis, or radiology apparent peritoneal-surface only metastatic disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Leukocytes \>= 3,000/uL
✓. Absolute neutrophil count \>= 1,500/uL
✓. Platelets \>= 60,000/Ul
✓. Serum creatinine \<= 1.5 mg/dL 5)Distant metastatic disease of peritoneum may be visualized on imaging:
✓. Positive peritoneal cytology only
✓. Carcinomatosis on diagnostic laparoscopy or laparotomy.

Exclusion criteria

✕. Solid organ metastases (liver, central nervous system, lung). 2) Infections such as pneumonia or wound infections that would preclude protocol therapy.

What they're measuring

To assess improvements in survival in gastric adenocarcinoma patients with occult or apparent carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Timeframe: From enrollment up to 60 months

Trial details

NCT IDNCT07178808

SponsorBanner Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2031-02-22

View on ClinicalTrials.gov More Gastric Adenocarcinoma trials